These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 28710307)
1. Is it safe to acutely discontinue insulin therapy in patients with chronic hyperglycaemia starting GLP-1R agonists? Okiro JO; Mc Hugh C; Abdalla A BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28710307 [TBL] [Abstract][Full Text] [Related]
2. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Trujillo JM; Nuffer W Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096 [TBL] [Abstract][Full Text] [Related]
3. SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes. Shaughnessy AF Am Fam Physician; 2021 Aug; 104(2):206. PubMed ID: 34383432 [No Abstract] [Full Text] [Related]
4. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Yu M; Van Brunt K; Varnado OJ; Boye KS Diabetes Obes Metab; 2016 Apr; 18(4):419-24. PubMed ID: 26691396 [TBL] [Abstract][Full Text] [Related]
5. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide. Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401 [TBL] [Abstract][Full Text] [Related]
6. Addition of glucagon-like peptide-1 receptor agonist therapy to insulin in C-peptide-positive patients with type 1 diabetes. Kuhadiya ND; Prohaska B; Ghanim H; Dandona P Diabetes Obes Metab; 2019 Apr; 21(4):1054-1057. PubMed ID: 30536789 [TBL] [Abstract][Full Text] [Related]
8. GLP-1R agonist therapy for diabetes: benefits and potential risks. Samson SL; Garber A Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741 [TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Gentilella R; Pechtner V; Corcos A; Consoli A Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747 [TBL] [Abstract][Full Text] [Related]
10. Two new GLP-1 receptor agonists for diabetes. Med Lett Drugs Ther; 2014 Nov; 56(1455):109-11. PubMed ID: 25372847 [No Abstract] [Full Text] [Related]
11. Dulaglutide for the treatment of type 2 diabetes. Scheen AJ Expert Opin Biol Ther; 2017 Apr; 17(4):485-496. PubMed ID: 28274140 [TBL] [Abstract][Full Text] [Related]
12. Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. Scheen AJ Expert Rev Clin Pharmacol; 2016; 9(3):385-99. PubMed ID: 26761217 [TBL] [Abstract][Full Text] [Related]
13. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes]. Scheen AJ Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248 [TBL] [Abstract][Full Text] [Related]
14. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Skrivanek Z; Gaydos BL; Chien JY; Geiger MJ; Heathman MA; Berry S; Anderson JH; Forst T; Milicevic Z; Berry D Diabetes Obes Metab; 2014 Aug; 16(8):748-56. PubMed ID: 24762094 [TBL] [Abstract][Full Text] [Related]